Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

RALPH J HAUKE

Allopathic & Osteopathic Physicians Internal Medicine Hematology & Oncology

NPI
1578511283
CMS profile
297671
Location
OMAHA, NE

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2021 · Entire year

$780.92

3 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2021 · entire year · sorted by reported total

Nature of paymentAmountRecords
Consulting Fee $757.50 1
Education $23.42 2

By paying entity

PY2021 · entire year · sorted by reported total

Paying entityAmountRecords
Janssen Scientific Affairs, LLC $757.50 1
Gilead Sciences, Inc. $11.92 1
Epizyme, Inc., $11.50 1

Page 1 of 1; records 1–3 of 3 matching records. This page contains 3 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

RALPH J HAUKE

NPI 1578511283 · CMS profile ID 297671

Allopathic & Osteopathic Physicians / Internal Medicine / Hematology & Oncology

OMAHA, NE

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–3 of 3 matching records. This page contains 3 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1578511283?year=2021&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
RALPH J HAUKE, NPI 1578511283, CMS profile ID 297671. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–3 of 3 matching records. This page contains 3 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1578511283?year=2021&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
APA 7
IndustryPayments. (2026). RALPH J HAUKE, NPI 1578511283, CMS profile ID 297671. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–3 of 3 matching records. This page contains 3 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1578511283?year=2021&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
Bluebook
RALPH J HAUKE, NPI 1578511283, CMS profile ID 297671, IndustryPayments, General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–3 of 3 matching records. This page contains 3 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202. https://industrypayments.org/provider/npi-1578511283?year=2021&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2021

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2021 · Physicians and non-physician practitioners · CMS publication 2026-06-30

3 matching records · $780.92 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 3 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–3 of 3.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Janssen Scientific Affairs, LLC $757.5011/30/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788401241 CMS
Gilead Sciences, Inc. $11.9206/01/2021 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 845873991 CMS
Epizyme, Inc., $11.5003/04/2021 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 832340057 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $7,629.00 9
PY2020 $7.49 1
PY2021 $780.92 3
PY2023 $16.02 1
PY2024 $225.23 10
PY2025 $31.33 1

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2023, 2024, 2025
Source files and profile matching
Source files
Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2023 , PY2024 , PY2025
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Recipient $609.30 2
PY2025 Principal investigator $1,167,738.55 292
PY2024 Principal investigator $1,299,594.58 212
PY2023 Principal investigator $2,735,258.21 252
PY2022 Recipient $4,157.00 1
PY2022 Principal investigator $1,567,591.67 137
PY2021 Principal investigator $2,060,900.77 213
PY2020 Recipient $705.81 1
PY2020 Principal investigator $1,867,000.72 289
PY2019 Principal investigator $1,377,455.65 354

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2024

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

212 records in PY2024

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 ABBVIE INC. $1,200.00 12/31/2024 Non-covered Recipient Entity
NEBRASKA CANCER SPECIALISTS
A Global First-in-Human Study in NSCLC, HNSCC and Solid Tumors with ABBV-514 as a Single Agent and in Combination with Budigalimab No dispute reported 06/30/2026 1100766907
Principal investigator 1 ABBVIE INC. $4,128.30 12/24/2024 Non-covered Recipient Entity
ONCHEMATOLOGY WEST PC NEBRASKA CANCER SPECIALISTS
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer (NSCLC) Head and Neck Squamous Cell Carcinoma (HNSCC) and Other Solid Tumors Receiving Intravenous (IV) Infusion of ABBV-514 Alone or in Combination With Pembrolizumab or Budigalimab No dispute reported 06/30/2026 1100762450
Principal investigator 1 ABBVIE INC. $3,750.30 12/24/2024 Non-covered Recipient Entity
ONCHEMATOLOGY WEST PC NEBRASKA CANCER SPECIALISTS
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer (NSCLC) Head and Neck Squamous Cell Carcinoma (HNSCC) and Other Solid Tumors Receiving Intravenous (IV) Infusion of ABBV-514 Alone or in Combination With Pembrolizumab or Budigalimab No dispute reported 06/30/2026 1100762452
Principal investigator 1 ABBVIE INC. $1,066.50 12/24/2024 Non-covered Recipient Entity
ONCHEMATOLOGY WEST PC NEBRASKA CANCER SPECIALISTS
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer (NSCLC) Head and Neck Squamous Cell Carcinoma (HNSCC) and Other Solid Tumors Receiving Intravenous (IV) Infusion of ABBV-514 Alone or in Combination With Pembrolizumab or Budigalimab No dispute reported 06/30/2026 1100762454
Principal investigator 1 ABBVIE INC. $1,236.60 12/24/2024 Non-covered Recipient Entity
ONCHEMATOLOGY WEST PC NEBRASKA CANCER SPECIALISTS
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer (NSCLC) Head and Neck Squamous Cell Carcinoma (HNSCC) and Other Solid Tumors Receiving Intravenous (IV) Infusion of ABBV-514 Alone or in Combination With Pembrolizumab or Budigalimab No dispute reported 06/30/2026 1100762456
Principal investigator 1 ABBVIE INC. $1,188.00 12/24/2024 Non-covered Recipient Entity
ONCHEMATOLOGY WEST PC NEBRASKA CANCER SPECIALISTS
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer (NSCLC) Head and Neck Squamous Cell Carcinoma (HNSCC) and Other Solid Tumors Receiving Intravenous (IV) Infusion of ABBV-514 Alone or in Combination With Pembrolizumab or Budigalimab No dispute reported 06/30/2026 1100762458
Principal investigator 1 ABBVIE INC. $1,205.55 12/24/2024 Non-covered Recipient Entity
ONCHEMATOLOGY WEST PC NEBRASKA CANCER SPECIALISTS
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer (NSCLC) Head and Neck Squamous Cell Carcinoma (HNSCC) and Other Solid Tumors Receiving Intravenous (IV) Infusion of ABBV-514 Alone or in Combination With Pembrolizumab or Budigalimab No dispute reported 06/30/2026 1100762460
Principal investigator 1 ABBVIE INC. $1,948.05 12/24/2024 Non-covered Recipient Entity
ONCHEMATOLOGY WEST PC NEBRASKA CANCER SPECIALISTS
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer (NSCLC) Head and Neck Squamous Cell Carcinoma (HNSCC) and Other Solid Tumors Receiving Intravenous (IV) Infusion of ABBV-514 Alone or in Combination With Pembrolizumab or Budigalimab No dispute reported 06/30/2026 1100762462
Principal investigator 1 ABBVIE INC. $1,236.60 12/24/2024 Non-covered Recipient Entity
ONCHEMATOLOGY WEST PC NEBRASKA CANCER SPECIALISTS
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer (NSCLC) Head and Neck Squamous Cell Carcinoma (HNSCC) and Other Solid Tumors Receiving Intravenous (IV) Infusion of ABBV-514 Alone or in Combination With Pembrolizumab or Budigalimab No dispute reported 06/30/2026 1100762466
Principal investigator 1 ABBVIE INC. $4,000.00 12/02/2024 Non-covered Recipient Entity
ONCHEMATOLOGY WEST PC NEBRASKA CANCER SPECIALISTS
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer (NSCLC) Head and Neck Squamous Cell Carcinoma (HNSCC) and Other Solid Tumors Receiving Intravenous (IV) Infusion of ABBV-514 Alone or in Combination With Pembrolizumab or Budigalimab No dispute reported 06/30/2026 1100757349
Principal investigator 1 ABBVIE INC. $750.00 12/02/2024 Non-covered Recipient Entity
ONCHEMATOLOGY WEST PC NEBRASKA CANCER SPECIALISTS
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer (NSCLC) Head and Neck Squamous Cell Carcinoma (HNSCC) and Other Solid Tumors Receiving Intravenous (IV) Infusion of ABBV-514 Alone or in Combination With Pembrolizumab or Budigalimab No dispute reported 06/30/2026 1100757351
Principal investigator 1 ABBVIE INC. $3,896.10 11/28/2024 Non-covered Recipient Entity
ONCHEMATOLOGY WEST PC NEBRASKA CANCER SPECIALISTS
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer (NSCLC) Head and Neck Squamous Cell Carcinoma (HNSCC) and Other Solid Tumors Receiving Intravenous (IV) Infusion of ABBV-514 Alone or in Combination With Pembrolizumab or Budigalimab No dispute reported 06/30/2026 1100757153
Principal investigator 1 ABBVIE INC. $1,474.20 11/28/2024 Non-covered Recipient Entity
ONCHEMATOLOGY WEST PC NEBRASKA CANCER SPECIALISTS
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer (NSCLC) Head and Neck Squamous Cell Carcinoma (HNSCC) and Other Solid Tumors Receiving Intravenous (IV) Infusion of ABBV-514 Alone or in Combination With Pembrolizumab or Budigalimab No dispute reported 06/30/2026 1100757155
Principal investigator 1 ABBVIE INC. $675.00 11/20/2024 Non-covered Recipient Entity
ONCHEMATOLOGY WEST PC NEBRASKA CANCER SPECIALISTS
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer (NSCLC) Head and Neck Squamous Cell Carcinoma (HNSCC) and Other Solid Tumors Receiving Intravenous (IV) Infusion of ABBV-514 Alone or in Combination With Pembrolizumab or Budigalimab No dispute reported 06/30/2026 1100755949
Principal investigator 1 ABBVIE INC. $2,295.00 11/20/2024 Non-covered Recipient Entity
ONCHEMATOLOGY WEST PC NEBRASKA CANCER SPECIALISTS
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer (NSCLC) Head and Neck Squamous Cell Carcinoma (HNSCC) and Other Solid Tumors Receiving Intravenous (IV) Infusion of ABBV-514 Alone or in Combination With Pembrolizumab or Budigalimab No dispute reported 06/30/2026 1100755951
Principal investigator 1 ABBVIE INC. $2,295.00 11/20/2024 Non-covered Recipient Entity
ONCHEMATOLOGY WEST PC NEBRASKA CANCER SPECIALISTS
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer (NSCLC) Head and Neck Squamous Cell Carcinoma (HNSCC) and Other Solid Tumors Receiving Intravenous (IV) Infusion of ABBV-514 Alone or in Combination With Pembrolizumab or Budigalimab No dispute reported 06/30/2026 1100755953
Principal investigator 1 MACROGENICS, INC. $4,419.32 11/15/2024 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST P C
A STUDY OF LORIGERLIMAB WITH DOCETAXEL OR DOCETAXEL ALONE IN PARTICIPANTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER No dispute reported 06/30/2026 1127670040
Principal investigator 1 MACROGENICS, INC. $12,634.00 11/15/2024 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST P C
A STUDY OF LORIGERLIMAB WITH DOCETAXEL OR DOCETAXEL ALONE IN PARTICIPANTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER No dispute reported 06/30/2026 1127670042
Principal investigator 1 Novartis Pharmaceuticals Corporation $1,421.19 11/15/2024 Non-covered Recipient Entity
NEBRASKA CANCER SPECIALISTS
An Open-label, Randomized, Phase III Study Comparing 177Lu-PSMA-617 in Combination With Standard of Care, Versus Standard of Care Alone, in Adult Male Patients With Metastatic Hormone Sensitive Prostate Cancer (mHSPC) No dispute reported 06/30/2026 1089687521
Principal investigator 1 Hoffmann-La Roche Limited $8,000.00 11/12/2024 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST P.C.
Fixed dose IV combination of atezo tira No dispute reported 06/30/2026 1133412006
Principal investigator 1 Hoffmann-La Roche Limited $1,250.00 11/12/2024 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST P.C.
Fixed dose IV combination of atezo tira No dispute reported 06/30/2026 1133412008
Principal investigator 1 Hoffmann-La Roche Limited $1,000.00 11/12/2024 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST P.C.
Fixed dose IV combination of atezo tira No dispute reported 06/30/2026 1133412010
Principal investigator 1 Aveo Pharmaceuticals, Inc. $4,758.75 11/06/2024 Non-covered Recipient Entity
QCCA NETWORK LLC
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1143506353
Principal investigator 1 Aveo Pharmaceuticals, Inc. $472.50 11/06/2024 Non-covered Recipient Entity
QCCA NETWORK LLC
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1143506359
Principal investigator 1 Aveo Pharmaceuticals, Inc. $382.05 11/06/2024 Non-covered Recipient Entity
QCCA NETWORK LLC
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1143506365
Principal investigator 1 Aveo Pharmaceuticals, Inc. $382.05 11/06/2024 Non-covered Recipient Entity
QCCA NETWORK LLC
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1143506371
Principal investigator 1 Aveo Pharmaceuticals, Inc. $472.50 11/06/2024 Non-covered Recipient Entity
QCCA NETWORK LLC
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1143506376
Principal investigator 1 Aveo Pharmaceuticals, Inc. $4,758.75 11/06/2024 Non-covered Recipient Entity
QCCA NETWORK LLC
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1143506383
Principal investigator 1 Aveo Pharmaceuticals, Inc. $472.50 11/06/2024 Non-covered Recipient Entity
QCCA NETWORK LLC
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1143506390
Principal investigator 1 Aveo Pharmaceuticals, Inc. $382.05 11/06/2024 Non-covered Recipient Entity
QCCA NETWORK LLC
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1143506396
Principal investigator 1 Aveo Pharmaceuticals, Inc. $4,758.75 11/06/2024 Non-covered Recipient Entity
QCCA NETWORK LLC
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1143506403
Principal investigator 1 Aveo Pharmaceuticals, Inc. $4,758.75 11/06/2024 Non-covered Recipient Entity
QCCA NETWORK LLC
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1143506408
Principal investigator 1 Aveo Pharmaceuticals, Inc. $472.50 11/06/2024 Non-covered Recipient Entity
QCCA NETWORK LLC
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1143506415
Principal investigator 1 Aveo Pharmaceuticals, Inc. $382.05 11/06/2024 Non-covered Recipient Entity
QCCA NETWORK LLC
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1143506420
Principal investigator 1 MACROGENICS, INC. $4,697.00 11/06/2024 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST P C
A STUDY OF LORIGERLIMAB WITH DOCETAXEL OR DOCETAXEL ALONE IN PARTICIPANTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER No dispute reported 06/30/2026 1127670008
Principal investigator 1 ABBVIE INC. $1,422.90 10/30/2024 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer (NSCLC) Head and Neck Squamous Cell Carcinoma (HNSCC) and Other Solid Tumors Receiving Intravenous (IV) Infusion of ABBV-514 Alone or in Combination With Pembrolizumab or Budigalimab No dispute reported 06/30/2026 1100751053
Principal investigator 1 ABBVIE INC. $1,422.90 10/30/2024 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer (NSCLC) Head and Neck Squamous Cell Carcinoma (HNSCC) and Other Solid Tumors Receiving Intravenous (IV) Infusion of ABBV-514 Alone or in Combination With Pembrolizumab or Budigalimab No dispute reported 06/30/2026 1100751055
Principal investigator 1 ABBVIE INC. $4,603.50 10/30/2024 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer (NSCLC) Head and Neck Squamous Cell Carcinoma (HNSCC) and Other Solid Tumors Receiving Intravenous (IV) Infusion of ABBV-514 Alone or in Combination With Pembrolizumab or Budigalimab No dispute reported 06/30/2026 1100751057
Principal investigator 1 ABBVIE INC. $2,018.25 10/30/2024 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer (NSCLC) Head and Neck Squamous Cell Carcinoma (HNSCC) and Other Solid Tumors Receiving Intravenous (IV) Infusion of ABBV-514 Alone or in Combination With Pembrolizumab or Budigalimab No dispute reported 06/30/2026 1100751059
Principal investigator 1 Aveo Pharmaceuticals, Inc. $900.00 10/28/2024 Non-covered Recipient Entity
QCCA NETWORK LLC
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1143506341
Principal investigator 1 Aveo Pharmaceuticals, Inc. $900.00 10/28/2024 Non-covered Recipient Entity
QCCA NETWORK LLC
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1143506347
Principal investigator 1 Janssen Research & Development, LLC $212.00 10/25/2024 Non-covered Recipient Entity
US ONCOLOGY RESEARCH INC
A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for Treatment of Participants With Metastatic Prostate Cancer No dispute reported 06/30/2026 1079014372
Principal investigator 1 MACROGENICS, INC. $770.00 10/23/2024 Non-covered Recipient Entity
ADVARRA INC
A STUDY OF LORIGERLIMAB WITH DOCETAXEL OR DOCETAXEL ALONE IN PARTICIPANTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER No dispute reported 06/30/2026 1127669940
Principal investigator 1 MACROGENICS, INC. $770.00 10/23/2024 Non-covered Recipient Entity
ADVARRA INC
A STUDY OF LORIGERLIMAB WITH DOCETAXEL OR DOCETAXEL ALONE IN PARTICIPANTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER No dispute reported 06/30/2026 1127669952
Principal investigator 1 MACROGENICS, INC. $22,504.00 10/23/2024 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST P C
A STUDY OF LORIGERLIMAB WITH DOCETAXEL OR DOCETAXEL ALONE IN PARTICIPANTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER No dispute reported 06/30/2026 1127669966
Principal investigator 1 Janssen Research & Development, LLC $1,819.00 10/21/2024 Non-covered Recipient Entity
US ONCOLOGY RESEARCH INC
A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for Treatment of Participants With Metastatic Prostate Cancer No dispute reported 06/30/2026 1079013322
Principal investigator 1 Janssen Research & Development, LLC $51.00 10/21/2024 Non-covered Recipient Entity
US ONCOLOGY RESEARCH INC
A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for Treatment of Participants With Metastatic Prostate Cancer No dispute reported 06/30/2026 1079013670
Principal investigator 1 Janssen Research & Development, LLC $1,298.00 10/21/2024 Non-covered Recipient Entity
US ONCOLOGY RESEARCH INC
A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for Treatment of Participants With Metastatic Prostate Cancer No dispute reported 06/30/2026 1079013930
Principal investigator 1 Janssen Research & Development, LLC $1,996.00 10/21/2024 Non-covered Recipient Entity
US ONCOLOGY RESEARCH INC
A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for Treatment of Participants With Metastatic Prostate Cancer No dispute reported 06/30/2026 1079014460
Principal investigator 1 Janssen Research & Development, LLC $1,298.00 10/21/2024 Non-covered Recipient Entity
US ONCOLOGY RESEARCH INC
A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for Treatment of Participants With Metastatic Prostate Cancer No dispute reported 06/30/2026 1079014492
Principal investigator 1 Aveo Pharmaceuticals, Inc. $500.00 10/16/2024 Non-covered Recipient Entity
QCCA NETWORK LLC
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1143506337
Principal investigator 1 Astellas Pharma Global Development $1,030.00 10/11/2024 Covered Recipient Teaching Hospital
Nebraska Methodist Hospital
A Multinational, Phase 3, Randomized, Double-blind, Placebo-controlled Efficacy and Safety Study of Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus ADT in Patients with Metastatic Hormone Sensitive Prostate Cancer (mHSPC) No dispute reported 06/30/2026 1134121568
Principal investigator 1 MACROGENICS, INC. $500.00 10/09/2024 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST P C
A STUDY OF LORIGERLIMAB WITH DOCETAXEL OR DOCETAXEL ALONE IN PARTICIPANTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER No dispute reported 06/30/2026 1127669850
Principal investigator 1 MACROGENICS, INC. $6,317.00 10/02/2024 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST P C
A STUDY OF LORIGERLIMAB WITH DOCETAXEL OR DOCETAXEL ALONE IN PARTICIPANTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER No dispute reported 06/30/2026 1127669832
Principal investigator 1 MACROGENICS, INC. $819.00 10/02/2024 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST P C
A STUDY OF LORIGERLIMAB WITH DOCETAXEL OR DOCETAXEL ALONE IN PARTICIPANTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER No dispute reported 06/30/2026 1127669834
Principal investigator 1 MACROGENICS, INC. $671.00 10/02/2024 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST P C
A STUDY OF LORIGERLIMAB WITH DOCETAXEL OR DOCETAXEL ALONE IN PARTICIPANTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER No dispute reported 06/30/2026 1127669836
Principal investigator 1 Astellas Pharma Global Development $3,026.40 09/27/2024 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST P C
An Open-Label, Randomized Phase 3 Study to Evaluate Enfortumab Vedotin vs Chemotherapy in Subjects With Previously Treated Locally Advanced or Metastatic Urothelial Cancer (EV-301) No dispute reported 06/30/2026 1134124022
Principal investigator 1 MACROGENICS, INC. $940.80 09/25/2024 Non-covered Recipient Entity
ADVARRA INC
A STUDY OF LORIGERLIMAB WITH DOCETAXEL OR DOCETAXEL ALONE IN PARTICIPANTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER No dispute reported 06/30/2026 1127669804
Principal investigator 1 MACROGENICS, INC. $14,900.00 09/25/2024 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST P C
A STUDY OF LORIGERLIMAB WITH DOCETAXEL OR DOCETAXEL ALONE IN PARTICIPANTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER No dispute reported 06/30/2026 1127669806
Principal investigator 1 MACROGENICS, INC. $500.00 09/25/2024 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST P C
A STUDY OF LORIGERLIMAB WITH DOCETAXEL OR DOCETAXEL ALONE IN PARTICIPANTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER No dispute reported 06/30/2026 1127669808
Principal investigator 1 MACROGENICS, INC. $273.00 09/25/2024 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST P C
A STUDY OF LORIGERLIMAB WITH DOCETAXEL OR DOCETAXEL ALONE IN PARTICIPANTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER No dispute reported 06/30/2026 1127669810
Principal investigator 1 MACROGENICS, INC. $17,752.00 09/25/2024 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST P C
A STUDY OF LORIGERLIMAB WITH DOCETAXEL OR DOCETAXEL ALONE IN PARTICIPANTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER No dispute reported 06/30/2026 1127669812
Principal investigator 1 MACROGENICS, INC. $19,500.00 09/25/2024 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST P C
A STUDY OF LORIGERLIMAB WITH DOCETAXEL OR DOCETAXEL ALONE IN PARTICIPANTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER No dispute reported 06/30/2026 1127669814
Principal investigator 1 BioNTech SE $250.00 09/24/2024 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST PC
BNT111-01 No dispute reported 06/30/2026 1150664936
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $4,828.85 09/20/2024 Non-covered Recipient Entity
Us Oncology Research Llc
BAY 888223, A phase III randomized, double-blind, placebo-controlled trial of radium-223 dichloride in combination with abiraterone acetate and prednisone/prednisolone in the treatment of asymptomatic or mildly symptomatic chemotherapy-nave subjects with No dispute reported 06/30/2026 1156029946
Principal investigator 1 ABBVIE INC. $2,700.00 09/18/2024 Non-covered Recipient Entity
ONCHEMATOLOGY WEST PC NEBRASKA CANCER SPECIALISTS
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer (NSCLC) Head and Neck Squamous Cell Carcinoma (HNSCC) and Other Solid Tumors Receiving Intravenous (IV) Infusion of ABBV-514 Alone or in Combination With Pembrolizumab or Budigalimab No dispute reported 06/30/2026 1100743048
Principal investigator 1 Astellas Pharma Global Development $464.00 09/12/2024 Covered Recipient Teaching Hospital
Nebraska Methodist Hospital
A Phase 2 Open-label Extension Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study No dispute reported 06/30/2026 1134121564
Principal investigator 1 MACROGENICS, INC. $26,622.62 09/11/2024 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST P C
A STUDY OF LORIGERLIMAB WITH DOCETAXEL OR DOCETAXEL ALONE IN PARTICIPANTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER No dispute reported 06/30/2026 1127669746
Principal investigator 1 Astellas Pharma Global Development $1,250.00 09/05/2024 Covered Recipient Teaching Hospital
Nebraska Methodist Hospital
A Phase 2 Open-label Extension Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study No dispute reported 06/30/2026 1134121566
Principal investigator 1 BioNTech SE $1,250.00 09/05/2024 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST PC
BNT111-01 No dispute reported 06/30/2026 1150664927
Principal investigator 1 BioNTech SE $750.00 09/05/2024 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST PC
BNT111-01 No dispute reported 06/30/2026 1150664933
Principal investigator 1 BioNTech SE $1,500.00 09/05/2024 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST PC
BNT111-01 No dispute reported 06/30/2026 1150664940
Principal investigator 1 MACROGENICS, INC. $6,317.00 09/04/2024 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST P C
A STUDY OF LORIGERLIMAB WITH DOCETAXEL OR DOCETAXEL ALONE IN PARTICIPANTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER No dispute reported 06/30/2026 1127669722
Principal investigator 1 BioNTech SE $8,359.00 08/27/2024 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST PC
BNT111-01 No dispute reported 06/30/2026 1150664929
Principal investigator 1 BioNTech SE $276.00 08/27/2024 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST PC
BNT111-01 No dispute reported 06/30/2026 1150664938
Principal investigator 1 MACROGENICS, INC. $1,621.00 08/09/2024 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST P C
A STUDY OF LORIGERLIMAB WITH DOCETAXEL OR DOCETAXEL ALONE IN PARTICIPANTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER No dispute reported 06/30/2026 1127669618
Principal investigator 1 MACROGENICS, INC. $6,317.00 08/09/2024 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST P C
A STUDY OF LORIGERLIMAB WITH DOCETAXEL OR DOCETAXEL ALONE IN PARTICIPANTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER No dispute reported 06/30/2026 1127669620
Principal investigator 1 MACROGENICS, INC. $16,576.00 08/09/2024 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST P C
A STUDY OF LORIGERLIMAB WITH DOCETAXEL OR DOCETAXEL ALONE IN PARTICIPANTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER No dispute reported 06/30/2026 1127669622
Principal investigator 1 MACROGENICS, INC. $3,725.77 08/09/2024 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST P C
A STUDY OF LORIGERLIMAB WITH DOCETAXEL OR DOCETAXEL ALONE IN PARTICIPANTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER No dispute reported 06/30/2026 1127669624
Principal investigator 1 MACROGENICS, INC. $500.00 08/07/2024 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST P C
A STUDY OF LORIGERLIMAB WITH DOCETAXEL OR DOCETAXEL ALONE IN PARTICIPANTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER No dispute reported 06/30/2026 1127669594
Principal investigator 1 Astellas Pharma Global Development $565.00 08/01/2024 Covered Recipient Teaching Hospital
Nebraska Methodist Hospital
A Phase 2 Open-label Extension Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study No dispute reported 06/30/2026 1134121562
Principal investigator 1 Aveo Pharmaceuticals, Inc. $127.67 07/31/2024 Non-covered Recipient Entity
QCCA NETWORK LLC
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1143506332
Principal investigator 1 BioNTech SE $833.00 07/23/2024 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST PC
BNT111-01 No dispute reported 06/30/2026 1150664931
Principal investigator 1 MACROGENICS, INC. $23,480.79 07/17/2024 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST P C
A STUDY OF LORIGERLIMAB WITH DOCETAXEL OR DOCETAXEL ALONE IN PARTICIPANTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER No dispute reported 06/30/2026 1127669550
Principal investigator 1 MACROGENICS, INC. $250.00 07/17/2024 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST P C
A STUDY OF LORIGERLIMAB WITH DOCETAXEL OR DOCETAXEL ALONE IN PARTICIPANTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER No dispute reported 06/30/2026 1127669552
Principal investigator 1 Exelixis Inc. $338.00 07/15/2024 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST PC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1138630538
Principal investigator 1 Exelixis Inc. $338.00 07/01/2024 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST PC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1138630536
Principal investigator 1 Novartis Pharmaceuticals Corporation $1,500.00 06/18/2024 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST NEBRASKA CANCER SPECIALIST
PSMAfore: A Phase III, Open-label, Multi-Center, Randomized Study Comparing 177Lu-PSMA-617 vs. a Change of Androgen Receptor-directed Therapy in the Treatment of Taxane Nave Men With Progressive Metastatic Castrate Resistant Prostate Cancer No dispute reported 06/30/2026 1089695141
Principal investigator 1 Janssen Research & Development, LLC $7,400.00 06/17/2024 Non-covered Recipient Entity
US ONCOLOGY RESEARCH INC
A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for Treatment of Participants With Metastatic Prostate Cancer No dispute reported 06/30/2026 1079013744
Principal investigator 1 MACROGENICS, INC. $5,975.00 06/14/2024 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST P C
A STUDY OF LORIGERLIMAB WITH DOCETAXEL OR DOCETAXEL ALONE IN PARTICIPANTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER No dispute reported 06/30/2026 1127669452
Principal investigator 1 Astellas Pharma Global Development $464.00 06/13/2024 Covered Recipient Teaching Hospital
Nebraska Methodist Hospital
A Phase 2 Open-label Extension Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study No dispute reported 06/30/2026 1134121560
Principal investigator 1 Janssen Research & Development, LLC $152.00 06/13/2024 Non-covered Recipient Entity
Us Oncology Research, Llc
A Phase 3 Randomized Placebo controlled Double blind Study of Apalutamide Plus Androgen Deprivation Therapy ADT Versus ADT in Subjects With Metastatic Hormone sensitive Prostate Cancer mHSPC No dispute reported 06/30/2026 1078961971
Principal investigator 1 MACROGENICS, INC. $440.00 06/07/2024 Non-covered Recipient Entity
ADVARRA INC
A STUDY OF LORIGERLIMAB WITH DOCETAXEL OR DOCETAXEL ALONE IN PARTICIPANTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER No dispute reported 06/30/2026 1127669388
Principal investigator 1 MACROGENICS, INC. $440.00 06/07/2024 Non-covered Recipient Entity
ADVARRA INC
A STUDY OF LORIGERLIMAB WITH DOCETAXEL OR DOCETAXEL ALONE IN PARTICIPANTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER No dispute reported 06/30/2026 1127669390
Principal investigator 1 MACROGENICS, INC. $85.00 06/07/2024 Non-covered Recipient Entity
ADVARRA INC
A STUDY OF LORIGERLIMAB WITH DOCETAXEL OR DOCETAXEL ALONE IN PARTICIPANTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER No dispute reported 06/30/2026 1127669400
Principal investigator 1 MACROGENICS, INC. $770.00 06/07/2024 Non-covered Recipient Entity
ADVARRA INC
A STUDY OF LORIGERLIMAB WITH DOCETAXEL OR DOCETAXEL ALONE IN PARTICIPANTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER No dispute reported 06/30/2026 1127669418
Principal investigator 1 MACROGENICS, INC. $770.00 06/07/2024 Non-covered Recipient Entity
ADVARRA INC
A STUDY OF LORIGERLIMAB WITH DOCETAXEL OR DOCETAXEL ALONE IN PARTICIPANTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER No dispute reported 06/30/2026 1127669428
Principal investigator 1 MACROGENICS, INC. $1,160.00 06/07/2024 Non-covered Recipient Entity
ADVARRA INC
A STUDY OF LORIGERLIMAB WITH DOCETAXEL OR DOCETAXEL ALONE IN PARTICIPANTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER No dispute reported 06/30/2026 1127669438
Principal investigator 1 MACROGENICS, INC. $23,094.73 06/05/2024 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST P C
A STUDY OF LORIGERLIMAB WITH DOCETAXEL OR DOCETAXEL ALONE IN PARTICIPANTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER No dispute reported 06/30/2026 1127669366
Principal investigator 1 Astellas Pharma Global Development $2,250.00 05/31/2024 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST P C
An Open-label, Multicenter, Multicohort, Phase 2 Study to Evaluate Enfortumab Vedotin in Subjects With Previously Treated Locally Advanced or Metastatic Malignant Solid Tumors (EV-202) No dispute reported 06/30/2026 1134124020
Principal investigator 1 Exelixis Inc. $15,114.11 05/29/2024 Non-covered Recipient Entity
Nebraska Cancer Specialists
A Phase 1b Dose Escalation Study of Cabozantinib (XL184) Administered alone or in Combination with Atezolizumab to Subjects with Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1138628826
Principal investigator 1 BioNTech SE $8,359.00 05/21/2024 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST PC
BNT111-01 No dispute reported 06/30/2026 1150664917
Principal investigator 1 BioNTech SE $500.00 05/21/2024 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST PC
BNT111-01 No dispute reported 06/30/2026 1150664919
Principal investigator 1 BioNTech SE $8,359.00 05/21/2024 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST PC
BNT111-01 No dispute reported 06/30/2026 1150664921
Principal investigator 1 BioNTech SE $276.00 05/21/2024 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST PC
BNT111-01 No dispute reported 06/30/2026 1150664923
Principal investigator 1 BioNTech SE $276.00 05/21/2024 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST PC
BNT111-01 No dispute reported 06/30/2026 1150664925
Principal investigator 1 MACROGENICS, INC. $4,419.32 05/15/2024 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST P C
A STUDY OF LORIGERLIMAB WITH DOCETAXEL OR DOCETAXEL ALONE IN PARTICIPANTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER No dispute reported 06/30/2026 1127669256
Principal investigator 1 Aveo Pharmaceuticals, Inc. $472.50 05/14/2024 Non-covered Recipient Entity
QCCA NETWORK LLC
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1143506281
Principal investigator 1 Aveo Pharmaceuticals, Inc. $382.05 05/14/2024 Non-covered Recipient Entity
QCCA NETWORK LLC
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1143506285
Principal investigator 1 Aveo Pharmaceuticals, Inc. $4,758.75 05/14/2024 Non-covered Recipient Entity
QCCA NETWORK LLC
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1143506291
Principal investigator 1 Aveo Pharmaceuticals, Inc. $472.50 05/14/2024 Non-covered Recipient Entity
QCCA NETWORK LLC
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1143506294
Principal investigator 1 Aveo Pharmaceuticals, Inc. $4,758.75 05/14/2024 Non-covered Recipient Entity
QCCA NETWORK LLC
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1143506297
Principal investigator 1 Aveo Pharmaceuticals, Inc. $4,758.75 05/14/2024 Non-covered Recipient Entity
QCCA NETWORK LLC
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1143506300
Principal investigator 1 Aveo Pharmaceuticals, Inc. $472.50 05/14/2024 Non-covered Recipient Entity
QCCA NETWORK LLC
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1143506306
Principal investigator 1 Aveo Pharmaceuticals, Inc. $382.05 05/14/2024 Non-covered Recipient Entity
QCCA NETWORK LLC
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1143506312
Principal investigator 1 Aveo Pharmaceuticals, Inc. $382.05 05/14/2024 Non-covered Recipient Entity
QCCA NETWORK LLC
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1143506320
Principal investigator 1 MACROGENICS, INC. $85.00 05/01/2024 Non-covered Recipient Entity
ADVARRA INC
A STUDY OF LORIGERLIMAB WITH DOCETAXEL OR DOCETAXEL ALONE IN PARTICIPANTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER No dispute reported 06/30/2026 1127669164
Principal investigator 1 MACROGENICS, INC. $85.00 05/01/2024 Non-covered Recipient Entity
ADVARRA INC
A STUDY OF LORIGERLIMAB WITH DOCETAXEL OR DOCETAXEL ALONE IN PARTICIPANTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER No dispute reported 06/30/2026 1127669174
Principal investigator 1 MACROGENICS, INC. $580.00 05/01/2024 Non-covered Recipient Entity
ADVARRA INC
A STUDY OF LORIGERLIMAB WITH DOCETAXEL OR DOCETAXEL ALONE IN PARTICIPANTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER No dispute reported 06/30/2026 1127669184
Principal investigator 1 MACROGENICS, INC. $85.00 05/01/2024 Non-covered Recipient Entity
ADVARRA INC
A STUDY OF LORIGERLIMAB WITH DOCETAXEL OR DOCETAXEL ALONE IN PARTICIPANTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER No dispute reported 06/30/2026 1127669194
Principal investigator 1 MACROGENICS, INC. $6,317.00 05/01/2024 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST P C
A STUDY OF LORIGERLIMAB WITH DOCETAXEL OR DOCETAXEL ALONE IN PARTICIPANTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER No dispute reported 06/30/2026 1127669204
Principal investigator 1 Exelixis Inc. $4,604.00 04/19/2024 Non-covered Recipient Entity
Nebraska Cancer Specialists
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XL092 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1138628818
Principal investigator 1 Exelixis Inc. $370.00 04/19/2024 Non-covered Recipient Entity
Nebraska Cancer Specialists
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XL092 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1138628820
Principal investigator 1 Exelixis Inc. $2,970.00 04/19/2024 Non-covered Recipient Entity
Nebraska Cancer Specialists
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XL092 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1138628822
Principal investigator 1 Exelixis Inc. $335.00 04/19/2024 Non-covered Recipient Entity
Nebraska Cancer Specialists
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XL092 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1138628824
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $77,308.50 04/18/2024 Non-covered Recipient Entity
Oncology Hematology West P.c. Dba Nebraska Cancer Specialists
A Phase 2 Randomized Study of Relatlimab Plus Nivolumab in Combination With Chemotherapy vs. Nivolumab in Combination With Chemotherapy as First Line Treatment for Participants With Stage IV or Recurrent Non-small Cell Lung Cancer (NSCLC) No dispute reported 06/30/2026 1123479007
Principal investigator 1 MACROGENICS, INC. $18,951.00 04/17/2024 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST P C
A STUDY OF LORIGERLIMAB WITH DOCETAXEL OR DOCETAXEL ALONE IN PARTICIPANTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER No dispute reported 06/30/2026 1127669098
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $7,750.00 04/11/2024 Non-covered Recipient Entity
Nebraska Cancer Specialists
Phase I/II IL8 Nivo Combo Study in advanced solid tumors & post PD1 MelanomaStudy No dispute reported 06/30/2026 1123478611
Principal investigator 1 Exelixis Inc. $11,000.00 04/10/2024 Non-covered Recipient Entity
Nebraska Cancer Specialists
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XL092 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1138628812
Principal investigator 1 Exelixis Inc. $1,000.00 04/10/2024 Non-covered Recipient Entity
Nebraska Cancer Specialists
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XL092 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1138628814
Principal investigator 1 Exelixis Inc. $1,250.00 04/10/2024 Non-covered Recipient Entity
Nebraska Cancer Specialists
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XL092 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1138628816
Principal investigator 1 MACROGENICS, INC. $7,555.33 04/03/2024 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST P C
A STUDY OF LORIGERLIMAB WITH DOCETAXEL OR DOCETAXEL ALONE IN PARTICIPANTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER No dispute reported 06/30/2026 1127669060
Principal investigator 1 Aveo Pharmaceuticals, Inc. $2,349.00 03/27/2024 Non-covered Recipient Entity
QCCA NETWORK, LLC
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1143506270
Principal investigator 1 Aveo Pharmaceuticals, Inc. $2,505.60 03/22/2024 Non-covered Recipient Entity
QCCA NETWORK, LLC
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1143506267
Principal investigator 1 MACROGENICS, INC. $70.00 03/22/2024 Non-covered Recipient Entity
ADVARRA INC
A STUDY OF LORIGERLIMAB WITH DOCETAXEL OR DOCETAXEL ALONE IN PARTICIPANTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER No dispute reported 06/30/2026 1127669012
Principal investigator 1 MACROGENICS, INC. $250.00 03/22/2024 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST P C
A STUDY OF LORIGERLIMAB WITH DOCETAXEL OR DOCETAXEL ALONE IN PARTICIPANTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER No dispute reported 06/30/2026 1127669028
Principal investigator 1 MACROGENICS, INC. $29,450.17 03/15/2024 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST P C
A STUDY OF LORIGERLIMAB WITH DOCETAXEL OR DOCETAXEL ALONE IN PARTICIPANTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER No dispute reported 06/30/2026 1127668950
Principal investigator 1 Astellas Pharma Global Development $565.00 03/14/2024 Covered Recipient Teaching Hospital
Nebraska Methodist Hospital
A Phase 2 Open-label Extension Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study No dispute reported 06/30/2026 1134121558
Principal investigator 1 Aveo Pharmaceuticals, Inc. $472.50 03/13/2024 Non-covered Recipient Entity
QCCA NETWORK, LLC
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1143506249
Principal investigator 1 Aveo Pharmaceuticals, Inc. $382.05 03/13/2024 Non-covered Recipient Entity
QCCA NETWORK, LLC
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1143506255
Principal investigator 1 Aveo Pharmaceuticals, Inc. $4,758.75 03/13/2024 Non-covered Recipient Entity
QCCA NETWORK, LLC
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1143506260
Principal investigator 1 Aveo Pharmaceuticals, Inc. $1,000.00 03/07/2024 Non-covered Recipient Entity
QCCA NETWORK, LLC
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1143506238
Principal investigator 1 Aveo Pharmaceuticals, Inc. $750.00 03/07/2024 Non-covered Recipient Entity
QCCA NETWORK, LLC
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1143506243
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $22,600.00 03/07/2024 Non-covered Recipient Entity
Oncology Hematology West P.c. Dba Nebraska Cancer Specialists
A Phase 2 Randomized Double-blind Study of Relatlimab Plus Nivolumab in Combination With Chemotherapy vs. Nivolumab in Combination With Chemotherapy as First Line Treatment for Participants With Stage IV or Recurrent Non-small Cell Lung Cancer (NSCLC) No dispute reported 06/30/2026 1155196623
Principal investigator 1 Exelixis Inc. $1,000.00 03/04/2024 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST PC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1138630480
Principal investigator 1 Exelixis Inc. $2,500.00 03/04/2024 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST PC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1138630482
Principal investigator 1 Exelixis Inc. $2,000.00 03/04/2024 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST PC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1138630484
Principal investigator 1 Exelixis Inc. $2,000.00 03/04/2024 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST PC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1138630486
Principal investigator 1 Exelixis Inc. $2,000.00 03/04/2024 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST PC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1138630488
Principal investigator 1 Exelixis Inc. $1,250.00 03/04/2024 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST PC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1138630490
Principal investigator 1 Exelixis Inc. $2,000.00 03/04/2024 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST PC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1138630492
Principal investigator 1 Exelixis Inc. $4,000.00 03/04/2024 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST PC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1138630494
Principal investigator 1 Exelixis Inc. $500.00 03/04/2024 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST PC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1138630496
Principal investigator 1 Exelixis Inc. $5,000.00 03/04/2024 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST PC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1138630498
Principal investigator 1 Exelixis Inc. $1,671.00 03/04/2024 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST PC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1138630500
Principal investigator 1 Exelixis Inc. $12,000.00 03/04/2024 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST PC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1138630502
Principal investigator 1 Aveo Pharmaceuticals, Inc. $2,374.65 02/28/2024 Non-covered Recipient Entity
QCCA NETWORK, LLC
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1143506224
Principal investigator 1 Aveo Pharmaceuticals, Inc. $2,675.70 02/28/2024 Non-covered Recipient Entity
QCCA NETWORK, LLC
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1143506233
Principal investigator 1 Aveo Pharmaceuticals, Inc. $382.05 02/19/2024 Non-covered Recipient Entity
QCCA NETWORK, LLC
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1143506197
Principal investigator 1 Aveo Pharmaceuticals, Inc. $100.00 02/19/2024 Non-covered Recipient Entity
QCCA NETWORK, LLC
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1143506203
Principal investigator 1 Aveo Pharmaceuticals, Inc. $4,758.75 02/19/2024 Non-covered Recipient Entity
QCCA NETWORK, LLC
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1143506208
Principal investigator 1 Aveo Pharmaceuticals, Inc. $472.50 02/19/2024 Non-covered Recipient Entity
QCCA NETWORK, LLC
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1143506214
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $3,204.00 02/15/2024 Non-covered Recipient Entity
Oncology Hematology West P.c. Dba Nebraska Cancer Specialists
A Phase 2 Randomized Double-blind Study of Relatlimab Plus Nivolumab in Combination With Chemotherapy vs. Nivolumab in Combination With Chemotherapy as First Line Treatment for Participants With Stage IV or Recurrent Non-small Cell Lung Cancer (NSCLC) No dispute reported 06/30/2026 1155196621
Principal investigator 1 Aveo Pharmaceuticals, Inc. $472.50 02/12/2024 Non-covered Recipient Entity
QCCA NETWORK, LLC
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1143506181
Principal investigator 1 Aveo Pharmaceuticals, Inc. $382.05 02/12/2024 Non-covered Recipient Entity
QCCA NETWORK, LLC
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1143506185
Principal investigator 1 Aveo Pharmaceuticals, Inc. $4,758.75 02/12/2024 Non-covered Recipient Entity
QCCA NETWORK, LLC
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1143506191
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $41,917.00 02/12/2024 Non-covered Recipient Entity
Us Oncology Res Llc
Ph III MIBC Neoadjuvant 1L Bladder IDO + Nivo + chemo (FA-EFS & IA2-OS & 9th DMC) No dispute reported 06/30/2026 1123481060
Principal investigator 1 Novartis Pharmaceuticals Corporation $614.79 02/08/2024 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY
An open-label, multi-center, phase II platform study evaluating the efficacy and safety of NIS793 and other new investigational drug combinations with standard of care (SOC) anti-cancer therapy for the second line treatment of metastatic colorectal cancer (mCRC) No dispute reported 06/30/2026 1089687043
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $107,694.00 02/06/2024 Non-covered Recipient Entity
Nebraska Cancer Specialists
Phase III 1L Melanoma non-inferiority rela+nivo FDC SubQ vs. rela+nivo FDC IV No dispute reported 06/30/2026 1123478613
Principal investigator 1 Exelixis Inc. $750.00 01/24/2024 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST PC
A Randomized, Double-Blind, Controlled Phase 3 Study of Cabozantinib in Combination with Nivolumab and Ipilimumab versus Nivolumab and Ipilimumab in Subjects with Previously Untreated Advanced or Metastatic Renal Cell Carcinoma of Intermediate or Poor Risk No dispute reported 06/30/2026 1138630548
Principal investigator 1 Astellas Pharma Global Development $2,000.00 01/19/2024 Covered Recipient Teaching Hospital
Nebraska Methodist Hospital
A Phase 2 Open-label Extension Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study No dispute reported 06/30/2026 1134121552
Principal investigator 1 Astellas Pharma Global Development $8,000.00 01/19/2024 Covered Recipient Teaching Hospital
Nebraska Methodist Hospital
A Phase 2 Open-label Extension Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study No dispute reported 06/30/2026 1134121554
Principal investigator 1 Astellas Pharma Global Development $1,563.00 01/19/2024 Covered Recipient Teaching Hospital
Nebraska Methodist Hospital
A Phase 2 Open-label Extension Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study No dispute reported 06/30/2026 1134121556
Principal investigator 1 Novartis Pharmaceuticals Corporation $226,721.56 01/18/2024 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST NEBRASKA CANCER SPECIALIST
An Open-label, Randomized, Phase III Study Comparing 177Lu-PSMA-617 in Combination With Standard of Care, Versus Standard of Care Alone, in Adult Male Patients With Metastatic Hormone Sensitive Prostate Cancer (mHSPC) No dispute reported 06/30/2026 1089694691
Principal investigator 1 Aveo Pharmaceuticals, Inc. $2,182.95 01/17/2024 Non-covered Recipient Entity
QCCA NETWORK, LLC
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1143505890
Principal investigator 1 Aveo Pharmaceuticals, Inc. $472.50 01/17/2024 Non-covered Recipient Entity
QCCA NETWORK, LLC
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1143505897
Principal investigator 1 Aveo Pharmaceuticals, Inc. $382.05 01/17/2024 Non-covered Recipient Entity
QCCA NETWORK, LLC
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1143505902
Principal investigator 1 Aveo Pharmaceuticals, Inc. $382.05 01/17/2024 Non-covered Recipient Entity
QCCA NETWORK, LLC
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1143505908
Principal investigator 1 Aveo Pharmaceuticals, Inc. $4,758.75 01/17/2024 Non-covered Recipient Entity
QCCA NETWORK, LLC
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1143505914
Principal investigator 1 Aveo Pharmaceuticals, Inc. $472.50 01/17/2024 Non-covered Recipient Entity
QCCA NETWORK, LLC
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1143505920
Principal investigator 1 Aveo Pharmaceuticals, Inc. $382.05 01/17/2024 Non-covered Recipient Entity
QCCA NETWORK, LLC
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1143505926
Principal investigator 1 Aveo Pharmaceuticals, Inc. $4,758.75 01/17/2024 Non-covered Recipient Entity
QCCA NETWORK, LLC
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1143505930
Principal investigator 1 Aveo Pharmaceuticals, Inc. $472.50 01/17/2024 Non-covered Recipient Entity
QCCA NETWORK, LLC
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1143505938
Principal investigator 1 Aveo Pharmaceuticals, Inc. $472.50 01/17/2024 Non-covered Recipient Entity
QCCA NETWORK, LLC
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1143505944
Principal investigator 1 Aveo Pharmaceuticals, Inc. $382.05 01/17/2024 Non-covered Recipient Entity
QCCA NETWORK, LLC
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1143505951
Principal investigator 1 Aveo Pharmaceuticals, Inc. $382.05 01/17/2024 Non-covered Recipient Entity
QCCA NETWORK, LLC
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1143505958
Principal investigator 1 Aveo Pharmaceuticals, Inc. $472.50 01/17/2024 Non-covered Recipient Entity
QCCA NETWORK, LLC
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1143505966
Principal investigator 1 Aveo Pharmaceuticals, Inc. $382.05 01/17/2024 Non-covered Recipient Entity
QCCA NETWORK, LLC
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1143505971
Principal investigator 1 Aveo Pharmaceuticals, Inc. $353.70 01/17/2024 Non-covered Recipient Entity
QCCA NETWORK, LLC
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1143505975
Principal investigator 1 Aveo Pharmaceuticals, Inc. $4,758.75 01/17/2024 Non-covered Recipient Entity
QCCA NETWORK, LLC
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1143505982
Principal investigator 1 Aveo Pharmaceuticals, Inc. $4,758.75 01/17/2024 Non-covered Recipient Entity
QCCA NETWORK, LLC
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1143505988
Principal investigator 1 Aveo Pharmaceuticals, Inc. $4,758.75 01/17/2024 Non-covered Recipient Entity
QCCA NETWORK, LLC
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1143505994
Principal investigator 1 Aveo Pharmaceuticals, Inc. $472.50 01/17/2024 Non-covered Recipient Entity
QCCA NETWORK, LLC
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1143505999
Principal investigator 1 Aveo Pharmaceuticals, Inc. $500.00 01/17/2024 Non-covered Recipient Entity
QCCA NETWORK, LLC
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1143506004
Principal investigator 1 Aveo Pharmaceuticals, Inc. $4,758.75 01/17/2024 Non-covered Recipient Entity
QCCA NETWORK, LLC
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1143506010
Principal investigator 1 Aveo Pharmaceuticals, Inc. $472.50 01/17/2024 Non-covered Recipient Entity
QCCA NETWORK, LLC
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1143506017
Principal investigator 1 Aveo Pharmaceuticals, Inc. $382.05 01/17/2024 Non-covered Recipient Entity
QCCA NETWORK, LLC
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1143506021
Principal investigator 1 Aveo Pharmaceuticals, Inc. $472.50 01/17/2024 Non-covered Recipient Entity
QCCA NETWORK, LLC
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1143506027
Principal investigator 1 Aveo Pharmaceuticals, Inc. $382.05 01/17/2024 Non-covered Recipient Entity
QCCA NETWORK, LLC
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1143506032
Principal investigator 1 Aveo Pharmaceuticals, Inc. $472.50 01/17/2024 Non-covered Recipient Entity
QCCA NETWORK, LLC
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1143506039
Principal investigator 1 Aveo Pharmaceuticals, Inc. $4,758.75 01/17/2024 Non-covered Recipient Entity
QCCA NETWORK, LLC
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1143506047
Principal investigator 1 Aveo Pharmaceuticals, Inc. $4,758.75 01/17/2024 Non-covered Recipient Entity
QCCA NETWORK, LLC
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1143506052
Principal investigator 1 Aveo Pharmaceuticals, Inc. $382.05 01/17/2024 Non-covered Recipient Entity
QCCA NETWORK, LLC
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor No dispute reported 06/30/2026 1143506058
Principal investigator 1 BioNTech SE $483.65 01/16/2024 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST PC
BNT111-01 No dispute reported 06/30/2026 1150664911
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $65,149.00 01/15/2024 Non-covered Recipient Entity
Oncology Hematology West P.c. Dba Nebraska Cancer Specialists
Ph III MIBC Neoadjuvant 1L Bladder IDO + Nivo + chemo (FA-EFS & IA2-OS & 9th DMC) No dispute reported 06/30/2026 1123479009
Principal investigator 1 MACROGENICS, INC. $695.00 01/12/2024 Non-covered Recipient Entity
ADVARRA INC
A STUDY OF LORIGERLIMAB WITH DOCETAXEL OR DOCETAXEL ALONE IN PARTICIPANTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER No dispute reported 06/30/2026 1127668594
Principal investigator 1 MACROGENICS, INC. $695.00 01/12/2024 Non-covered Recipient Entity
ADVARRA INC
A STUDY OF LORIGERLIMAB WITH DOCETAXEL OR DOCETAXEL ALONE IN PARTICIPANTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER No dispute reported 06/30/2026 1127668596
Principal investigator 1 MACROGENICS, INC. $80.00 01/12/2024 Non-covered Recipient Entity
ADVARRA INC
A STUDY OF LORIGERLIMAB WITH DOCETAXEL OR DOCETAXEL ALONE IN PARTICIPANTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER No dispute reported 06/30/2026 1127668598
Principal investigator 1 MACROGENICS, INC. $30,932.33 01/12/2024 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST P C
A STUDY OF LORIGERLIMAB WITH DOCETAXEL OR DOCETAXEL ALONE IN PARTICIPANTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER No dispute reported 06/30/2026 1127668618
Principal investigator 1 BioNTech SE $8,359.00 01/05/2024 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST PC
BNT111-01 No dispute reported 06/30/2026 1150664913
Principal investigator 1 BioNTech SE $276.00 01/05/2024 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST PC
BNT111-01 No dispute reported 06/30/2026 1150664915
Principal investigator 1 Novartis Pharmaceuticals Corporation $89,147.38 01/02/2024 Non-covered Recipient Entity
NEBRASKA CANCER SPECIALISTS
An Open-label, Randomized, Phase III Study Comparing 177Lu-PSMA-617 in Combination With Standard of Care, Versus Standard of Care Alone, in Adult Male Patients With Metastatic Hormone Sensitive Prostate Cancer (mHSPC) No dispute reported 06/30/2026 1089687629